SEER Database Common Cancer Sites - Cancer Stat Facts. https://seer.cancer.gov/statfacts/html/common.html.

Lee WS, Yun SH, Chun HK, Lee WY, Yun HR, Kim J, et al. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Color Dis. 2007;22:699–704.

Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42:2212–21.

Yoo PS, Lopez-Soler RI, Longo WE, Cha CH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer. 2006;6:202–7.

CAS  Article  Google Scholar 

Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677–83.

•• Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;37:1609–18 The major phase III randomized controlled trial comparing first-line FOLFOXIRI plus bevacizumab to FOLFIRI plus bevacizumab in 508 patients with results showing statistically significant improvement in progression free survival and objective response rate in the triplet chemotherapy plus bevacizumab arm.

Article  Google Scholar 

• Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–15 Updated analysis of the TRIBE study showing statistically significant improvement in overall survivial in the FOLFOXIRI plus bevacizumab arm.

CAS  Article  Google Scholar 

• Hurwitz HI, Tan BR, Reeves JA, et al. Phase II randomized trial of sequential or concurrent FOLFOXIRI–bevacizumab versus FOLFOX–bevacizumab for metastatic colorectal cancer (STEAM). Oncologist. 2019;24:921–32 Largest study in the U.S. comparing concurrent FOLFOXIRI plus bevacizumab vs sequential FOLFOXIRI plus bevacizumab vs FOLFOX plus bevacizumab in 280 patients with previously untreated metastatic colorectal cancer with results showing improvement in progression free survival, objective response rate, and liver resection rates in the concurrent and sequential FOLFOXIRI arms compared to the FOLFOX arm.

CAS  Article  Google Scholar 

Schmoll H-J, Meinert FM, Cygon F, Garlipp B, Junghanss C, Leithäuser M, et al. “CHARTA”: FOLFOX/bevacizumab vs. FOLFOXIRI/bevacizumab in advanced colorectal cancer—final results, prognostic and potentially predictive factors from the randomized phase II trial of the AIO. J Clin Oncol. 2017;35:3533–3.

Benson AB, Al-Hawary MM, Arain MA, et al. NCCN guidelines version 2.2020 colon ancer continue NCCN guidelines panel disclosures.

Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–422.

Article  Google Scholar 

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29:44–70.

Hebbar M, Chibaudel B, André T, Louvet C, Smith D, Mineur L, et al. Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study. J Chemother. 2013;25:104–11.

Loupakis F, Stein A, Ychou M, Hermann F, Salud A, Österlund P. A review of clinical studies and practical guide for the administration of triplet chemotherapy regimens with bevacizumab in first-line metastatic colorectal. Cancer. 2015;11:293–308. https://doi.org/10.1007/s11523-015-0400-y.

Article  Google Scholar 

Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol Off J Eur Soc Med Oncol. 2015;26:702–8 A major phase II study in patients with unresectable liver metastatic disease conducted at 16 centers in Australia showed that FOLFOXIRI plus bevacizumab has higher resection rates, response rates, and prolonged progression free survival compared to mFOLFOX plus beavizumab.

Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:845–52.

Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, rand. Lancet Oncol. 2020;21:497–507.

Smith JJ, D’Angelica MI. Surgical management of hepatic metastases of colorectal cancer. Hematol Oncol Clin North Am. 2015;29:61–84.

Article  Google Scholar 

Jones RP, Malik HZ, Fenwick SW, Poston GJ. Perioperative chemotherapy for resectable colorectal liver metastases: where now? Eur J Surg Oncol. 2013;39:807–11.

CAS  Article  Google Scholar 

Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3:e170278. https://doi.org/10.1001/jamaoncol.2017.0278.

Article  PubMed  PubMed Central  Google Scholar 

Nemoto T, Endo S, Isohata N, Takayanagi D, Nemoto D, Aizawa M, et al. Two cases of advanced colorectal cancer achieving complete response by FOLFOXIRI plus bevacizumab-a case report. Gan To Kagaku Ryoho. 2019;46:2410–2.

Sastre J, Vieitez JM, Gomez-España MA, Gil Calle S, Salud Salvia A, Suárez BG, et al. Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs). J Clin Oncol. 2019;37:3507–7.